Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630497 | 0.95 | LSS (0.55) | LSSHDAC1HDAC6KMT2AMTOR | |
| Trifluoroacetic Acid SCHEMBL3631651 | 0.89 | KMT2A (0.51) | LSSHDAC1HDAC6KMT2AMTOR | |
| SCHEMBL3417449 | 0.86 | LSS (0.56) | LSSHDAC1HDAC6MTORHDAC3 | |
| Cadaverine Tartrate SCHEMBL3634786 | 0.85 | PPARA (0.51) | LSSHDAC1HDAC6KMT2AMTOR | |
| SCHEMBL24575984 | 0.85 | MTOR (0.69) | LSSHDAC1HDAC6KMT2AMTOR | |
| SCHEMBL12133623 | 0.84 | KMT2A (0.76) | HDAC1HDAC6KMT2AHDAC3HDAC2 | |
| SCHEMBL5988091 | 0.84 | HDAC1 (0.57) | HDAC1HDAC6KMT2AHDAC3HDAC2 | |
| SCHEMBL1695141 | 0.83 | MTOR (0.58) | LSSHDAC1HDAC6KMT2AMTOR | |
| SCHEMBL4403136 | 0.83 | EPHX2 (0.68) | HDAC1HDAC6KMT2AHDAC3HDAC8 | |
| SCHEMBL934145 | 0.82 | HDAC3 (0.60) | LSSHDAC1HDAC6MTORHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | claimed |
| JP-2007530524-A | — | — | 2007-11-01 | — | — | JP | claimed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | claimed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | SERVICIO ANDALUZ DE SALUD (ES) | 2022-05-12 | — | — | US | disclosed |
| CN-109824465-B | Method for synthesizing amide by amine oxide catalyzed by bipyridine manganese catalyst | 陕西师范大学 | 2022-01-04 | — | — | CN | disclosed |
| EP-3834888-A2 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | Servicio Andaluz De Salud (ES) | 2021-06-16 | — | — | EP | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| CN-1674883-A | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1517679-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000294-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | LSS 1266/4885HDAC1 346/4885HDAC6 1179/4885 |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | ADH1A, ADH5, ADH1C | LSS 2905/4885HDAC1 381/4885HDAC6 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.